Alterations in VHL as potential biomarkers in renal-cell carcinoma (Q37724576)

22 August 2017

1 reference

title

Alterations in VHL as potential biomarkers in renal-cell carcinoma (English)

1 reference

22 August 2017

0 references

Lucy Gossage

1

1 reference

PubMed ID

20368728

22 August 2017

Tim Eisen

series ordinal

2

1 reference

PubMed ID

20368728

22 August 2017

language of work or name

English

0 references

publication date

6 April 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

1 reference

22 August 2017

7

1 reference

22 August 2017

277-288

1 reference

22 August 2017

5

1 reference

The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients

22 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Clinical implications of hypoxia inducible factor in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

HAF : the new player in oxygen-independent HIF-1alpha degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Molecular basis of the VHL hereditary cancer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Tumour suppression by the human von Hippel-Lindau gene product

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Mutation and cancer: statistical study of retinoblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Mutations of the VHL tumour suppressor gene in renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The von hippel-lindau tumor suppressor protein: an update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Von Hippel-Lindau disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Multitasking by pVHL in tumour suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Transplacental carcinogenesis by stilbestrol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The role of VEGF receptors in angiogenesis; complex partnerships

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Targeted therapies in metastatic renal cancer in 2009.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Genotype-phenotype correlations in von Hippel-Lindau disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Mutations in the VHL gene in sporadic apparently congenital polycythemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

VHL protein alterations in sporadic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Mutational state of von Hippel-Lindau and adenomatous polyposis coli genes in renal tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Novel somatic mutations in the VHL gene in Swedish archived sporadic renal cell carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

VEGF as a key mediator of angiogenesis in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Targeting the hypoxia-inducible factor (HIF) pathway in cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.42

Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.

31 March 2020

1 reference

12 December 2020

Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.

1 reference

12 December 2020

Clinical features and natural history of von Hippel-Lindau disease

1 reference

12 December 2020

Tumor angiogenesis: therapeutic implications

1 reference

12 December 2020

VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation

1 reference

12 December 2020

Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.

1 reference

12 December 2020

von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.

1 reference

12 December 2020

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

12 December 2020

Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy

1 reference

12 December 2020

Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma

1 reference

12 December 2020

Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.

1 reference

12 December 2020

10.1038/NRCLINONC.2010.42

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20368728